Key Points
- CEO David James Lennon sold about 306,885 shares between March 2 and April 9 (primarily in early April), raising roughly $1.06 million; the company says the sales were to cover tax withholding on vested equity and were disclosed in an SEC filing.
- Whitehawk shares dipped about 4.5% to $3.39 following the transactions; the company has a market cap of ~$160 million, recently reported EPS of -$0.34 versus -$0.55 expected, and analysts remain mixed with an average "Hold" rating and a ~$6.50 price target.
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 14,500 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $3.38, for a total transaction of $49,010.00. Following the transaction, the chief executive officer owned 518,622 shares in the company, valued at approximately $1,752,942.36. This trade represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
David James Lennon also recently made the following trade(s):
- On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.40, for a total transaction of $217,413.00.
- On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.43, for a total transaction of $322,718.41.
- On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.51, for a total transaction of $359,406.45.
- On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.48, for a total transaction of $93,465.84.
- On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $16,881.00.
Whitehawk Therapeutics Trading Down 4.5%
Shares of WHWK opened at $3.39 on Friday. The firm has a market cap of $160.01 million, a PE ratio of 7.21 and a beta of 0.57. The company's 50 day simple moving average is $3.35 and its 200-day simple moving average is $2.71. Whitehawk Therapeutics, Inc. has a 12-month low of $1.39 and a 12-month high of $4.48.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.21.
Hedge Funds Weigh In On Whitehawk Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd purchased a new position in Whitehawk Therapeutics in the 4th quarter valued at $28,000. ABG Innovation Capital Partners III GP Ltd acquired a new stake in Whitehawk Therapeutics in the third quarter valued at $51,000. Geode Capital Management LLC lifted its holdings in Whitehawk Therapeutics by 11.4% in the fourth quarter. Geode Capital Management LLC now owns 425,440 shares of the company's stock valued at $1,030,000 after acquiring an additional 43,686 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Whitehawk Therapeutics in the third quarter valued at $84,000. Finally, Jane Street Group LLC lifted its holdings in Whitehawk Therapeutics by 177.3% in the fourth quarter. Jane Street Group LLC now owns 69,931 shares of the company's stock valued at $169,000 after acquiring an additional 44,716 shares during the period. 52.08% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms recently weighed in on WHWK. Oppenheimer began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price objective on the stock. Wall Street Zen lowered shares of Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Finally, JonesTrading began coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They issued a "buy" rating and a $7.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $6.50.
Check Out Our Latest Research Report on Whitehawk Therapeutics
About Whitehawk Therapeutics
(
Get Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
